Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-80
SponsorbioAffinity Technologies Inc.

About this trial

Evaluate FlowPath Lung Diagnostic Test of Sputum Samples to Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, \>6 to \<30 mm in Diameter, Determined by LDCT.

Eligibility criteria

Qualifiers

Is able to give signed informed consent and comply with study requirements.

≥50 - 80 years of age.

current smoker with smoking history of at least 20 pack-years or current non-smoker with smoking history of at least 20 pack-years who quit smoking within the past 15 years.

Has a >6 to <30 mm diameter lung nodule (found by lung cancer screening or found incidentally by CT scan) as determined by CT and is willing to provide a sputum sample for FlowPath Lung test within 6 weeks of the prestudy baseline CT scan.

Disqualifiers

Is unable to cough with sufficient exertion to produce a sputum sample (e.g., due to severe obstructive lung disease).

The dominant nodule is ground glass or part solid as determined by CT scan.

Has 5 or more nodules sized >4 mm.

The nodule sized >6 to <30 mm in diameter is a distal (subsegmental) endobronchial nodule or a perifissural nodule.

Trial design

Treatments tested in this trial

  • Standard medical treatment
  • Standard medical treatment

Treatment groups

2,063 Participants
are divided into 1 treatment group

Locations

7
VA Palo Alto Health Care System94304, Palo AltoCalifornia, United States
VA Western Colorado Health Care System81501, Grand JunctionColorado, United States
Bay Pines VA Healthcare System33744, Bay PinesFlorida, United States
Miami VA Healthcare System33125, MiamiFlorida, United States

Sponsors and collaborators

bioAffinity Technologies Inc.

Lead sponsor